Physician profile
David E Butters
NPI 1932272598
$189,239.38
in general payments reported to CMS, 2019-2025
61 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $16K · 2021: $18K · 2022: $16K · 2023: $62K · 2024: $28K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Consulting Fee: $11K · Honoraria: $8,925 · Travel and Lodging: $5,914 · Food and Beverage: $5,207 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,275 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,390.00 |
| Consulting Fee | $10,575.00 |
| Honoraria | $8,925.00 |
| Travel and Lodging | $5,913.68 |
| Food and Beverage | $5,207.47 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,275.00 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $79,106.56 | 2019-2025 | Vraylar, Qulipta, Synthroid |
| Allergan, INC. | $24,357.06 | 2019-2021 | |
| Axsome Therapeutics, INC. | $21,913.19 | 2022-2025 | Auvelity, Sunosi |
| Astrazeneca Pharmaceuticals LP | $16,065.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Idorsia Pharmaceuticals US INC | $13,331.05 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $13,126.25 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $11,900.84 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,491.19 | 2019-2023 | Gattex |
| Biohaven Pharmaceuticals, INC. | $1,282.08 | 2021 | |
| Amarin Pharma, INC. | $571.39 | 2020-2022 | |
| Lilly USA, LLC | $509.93 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.03 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $447.15 | 2022-2023 | |
| Astellas Pharma US INC | $426.59 | 2019-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $399.80 | 2019-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Butters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.